We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Tissue Regenix Launches DermaPure Biological Skin Scaffold

Tissue Regenix Launches DermaPure Biological Skin Scaffold

June 13, 2014

Tissue Regenix Group is rolling out its DermaPure decellularized dermis product across the U.S., the British devicemaker said. Initial shipments by the company’s stateside manufacturer, Community Tissue Services, are set to begin this week.

DermaPure works by taking human donor skin and removing the DNA and cells, using tissue Regenix’s patented dCELL process to leave a natural biological scaffold that can be placed in the wound. The product aids natural healing by attracting the patient’s own cells to the wound site, the company said.

The regenerative tissue product is primarily intended for use by physicians in acute settings as a skin substitute, Greg Bila, president of Tissue Regenix, told Device Daily Bulletin. Physicians can use DermaPure as they see fit to replace skin as an overlay, he said, adding the company “doesn’t claim specific indications” for the product as it is homologous and can be used wherever skin needs to be replaced.

Bila said the company met with the FDA in May and expects to be granted a Medicare Q code, allowing for the product’s use in outpatient settings beginning next year.

Bila predicts the product will prove cost-effective compared with multiple grafts, as only one application of the biologic scaffold is needed to help patients heal. He added that Tissue Regenix is about to start a U.S. study to gauge DermaPure’s cost versus other treatment applications.

Tissue Regenix estimates the U.S. wound healing device market at about $1.4 billion a year. Roughly 6.5 million U.S. patients are currently afflicted by chronic wounds, the company says. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Medical Devices Commercial Operations

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing